Atlas Trials

Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

Clinical trial NCT02820935 · COMPLETED

Trial details

NCT number
NCT02820935
Sponsor
Celgene Corporation
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Pharmacokinetics
Start date
2016-07-01
Primary completion
2016-09-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.